| Autor: |
Yu Guo, Xue-Ning Shen, Hui-Fu Wang, Shi-Dong Chen, Ya-Ru Zhang, Shu-Fen Chen, Mei Cui, Wei Cheng, Qiang Dong, Tao Ma, Jin-Tai Yu |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-13 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
1758-9193 |
| DOI: |
10.1186/s13195-023-01174-0 |
| Popis: |
Abstract Background Failures in drug trials strengthen the necessity to further determine the neuropathological events during the development of Alzheimer’s disease (AD). We sought to investigate the dynamic changes and performance of plasma biomarkers across the entire Alzheimer’s continuum in the Chinese population. Methods Plasma amyloid-β (Αβ)42, Aβ40, Aβ42/Aβ40, phosphorylated tau (p-tau)181, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) were measured utilizing the ultrasensitive single-molecule array technology across the AD continuum (n=206), wherein Aβ status was defined by the values of cerebrospinal fluid (CSF) Aβ42 or Aβ positron emission tomography (PET). Their trajectories were compared with those of putative CSF biomarkers. Results Plasma GFAP and p-tau181 increased only in Aβ-positive individuals throughout aging, whereas NfL increased with aging regardless of Aβ status. Among the plasma biomarkers studied, GFAP was the one that changed first. It had a prominent elevation early in the cognitively unimpaired (CU) A+T− phase (CU A+T− phase: 97.10±41.29 pg/ml; CU A−T− phase: 49.18±14.39 pg/ml; p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
